Has the French Pharma Industry valuation changed over the past few years?

Investors are relatively neutral on the French Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady. The industry is trading close to its 3-year average PE ratio of 20.1x. The 3-year average PS ratio of 2.4x is higher than the industry's current PS ratio of 1.9x.

How does French Pharma compare with similar industries?

There are no additional sub-industries under this industry.

French (CAC) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 22 Jun 2026	€106.1b	€54.6b	€5.3b	18.4x	20x	1.9x
Wed, 20 May 2026	€107.7b	€54.6b	€5.3b	18.7x	20.3x	2x
Fri, 17 Apr 2026	€115.5b	€54.0b	€5.4b	20.1x	21.4x	2.1x
Sun, 15 Mar 2026	€109.0b	€54.0b	€5.4b	20.8x	20.2x	2x
Tue, 10 Feb 2026	€113.0b	€53.8b	€5.5b	21.9x	20.6x	2.1x
Thu, 08 Jan 2026	€115.4b	€53.0b	€7.0b	22.3x	16.6x	2.2x
Sat, 06 Dec 2025	€118.1b	€53.0b	€7.0b	22.4x	17x	2.2x
Mon, 03 Nov 2025	€121.3b	€53.0b	€7.0b	22.3x	17.4x	2.3x
Wed, 01 Oct 2025	€109.3b	€52.9b	€6.9b	19.8x	15.8x	2.1x
Fri, 29 Aug 2025	€118.2b	€52.8b	€6.9b	19.4x	17.1x	2.2x
Sun, 27 Jul 2025	€117.5b	€52.1b	€6.7b	20.9x	17.7x	2.3x
Tue, 24 Jun 2025	€113.8b	€52.1b	€6.7b	18.6x	17.1x	2.2x
Thu, 22 May 2025	€126.9b	€52.1b	€6.7b	18.4x	19.1x	2.4x
Sat, 19 Apr 2025	€122.6b	€51.2b	€5.9b	17.8x	20.6x	2.4x
Mon, 17 Mar 2025	€146.2b	€51.2b	€5.9b	18x	24.6x	2.9x
Wed, 12 Feb 2025	€143.6b	€51.1b	€6.3b	18.6x	22.9x	2.8x
Fri, 10 Jan 2025	€134.3b	€55.2b	€5.1b	19.1x	26.4x	2.4x
Sun, 08 Dec 2024	€129.0b	€55.2b	€5.1b	19.5x	25.3x	2.3x
Tue, 05 Nov 2024	€136.6b	€55.2b	€5.1b	21x	26.8x	2.5x
Thu, 03 Oct 2024	€144.5b	€53.8b	€4.8b	22.4x	30.1x	2.7x
Sat, 31 Aug 2024	€140.9b	€53.8b	€4.8b	20.4x	29.4x	2.6x
Mon, 29 Jul 2024	€134.6b	€53.8b	€4.9b	21.6x	27.5x	2.5x
Wed, 26 Jun 2024	€127.9b	€52.9b	€5.2b	20.5x	24.7x	2.4x
Fri, 24 May 2024	€128.1b	€52.9b	€5.2b	22.4x	24.8x	2.4x
Sun, 21 Apr 2024	€122.6b	€52.7b	€6.0b	20.1x	20.3x	2.3x
Tue, 19 Mar 2024	€123.5b	€52.6b	€6.0b	20.3x	20.4x	2.3x
Thu, 15 Feb 2024	€121.4b	€53.0b	€6.3b	19.8x	19.4x	2.3x
Sat, 13 Jan 2024	€133.9b	€52.2b	€9.7b	19.7x	13.8x	2.6x
Mon, 11 Dec 2023	€121.2b	€52.2b	€9.7b	16.8x	12.5x	2.3x
Wed, 08 Nov 2023	€119.3b	€52.2b	€9.7b	16.2x	12.3x	2.3x
Fri, 06 Oct 2023	€142.8b	€52.6b	€9.3b	18.8x	15.4x	2.7x
Sun, 03 Sep 2023	€138.8b	€52.6b	€9.3b	20.9x	15x	2.6x
Tue, 01 Aug 2023	€136.4b	€52.6b	€9.2b	19.6x	14.8x	2.6x
Thu, 29 Jun 2023	€135.9b	€52.6b	€9.1b	15x	14.9x	2.6x


FR Market	0.35%
Healthcare	-3.57%
Pharma	-2.86%
Pharma	-2.86%

	Company	Last Price	7D	1Y	Valuation
	ALTHX THX Pharma Société Anonyme	€3.44	7.8% +€3.4m	350.3%	PS58.9x
	AB AB Science	€0.90	0.6% +€382.7k	-22.2%	PS58.3x

Announcement • Jun 20

AB Science Patent For Masitinib In The Treatment Of Metastatic Castrate Resistant Prostate Cancer Formally Granted In The United States With Protection Until 2042

AB Science SA announced that the United States Patent Office has formally granted a patent for methods of treating metastatic castrate resistant prostate cancer (mCRPC) with its lead compound masitinib. This new US patent (US 12,648,944) ensures intellectual property protection for masitinib until May 2042. This new US patent adds to the IP coverage already granted in Europe (EP4175639). Counterpart patent applications have also been filed in other major international markets. In metastatic prostate cancer, patients take hormone therapies (i.e., androgen-deprivation therapy) in first line and second line. Then when metastatic cancer advances patients have to be treated by chemotherapy. There is only one chemotherapy registered, docetaxel, and no drug in combination with docetaxel or replacement of docetaxel has improved PFS or OS and has been registered for the last 20 years. Masitinib is positioned in combination with docetaxel as a treatment of mCRPC patients who are eligible to chemotherapy. That is to say, it is administered directly following the metastatic hormone-sensitive prostate cancer (mHSPC) treatment space. Masitinib is one of the rare drugs to have generated positive data on progression free survival (PFS) in combination with docetaxel in this population. More specifically, this patent provides protection for masitinib and related compounds for the treatment of mCRPC in a patient subpopulation with low metastatic involvement (as measured by baseline alkaline phosphatase levels). This patient population is fully consistent with the results of the masitinib study AB12003 and the ongoing clinical development program of masitinib in mCRPC. The key results from study AB12003 include: Masitinib (6.0 mg/kg/day) plus docetaxel conferred a significant progression-free survival (PFS) benefit in mCRPC patients with baseline alkaline phosphatase levels (ALP) less than or equal to 250 IU/L; hazard ratio of 0.79 [0.64,0.97] (p=0.0087), corresponding to a 21% reduction in risk of progression relative to control. Assessment of PFS rates was convergent with this primary outcome, with 12-, 18-, and 24-month PFS rates showing significant improvement in favor of masitinib plus docetaxel relative to the control: 1.6-fold (p=0.0035), 1.9-fold (p=0.0001), and 1.9-fold (p=0.0028), respectively. A progressively greater masitinib treatment effect was observed for lower baseline ALP levels (i.e., less advanced metastatic disease), with a significant 47% reduced risk of progression in patients with ALP less than or equal to 100 IU/L (hazard ratio=0.53, p=0.002). The safety profile of masitinib plus docetaxel was acceptable and consistent with the known masitinib profile, with no new safety signals observed. Although localized disease is associated with high survival rates, metastatic prostate cancer still represents an unmet medical need with a 5-years survival rate of approximately 32%. Practically all patients with metastatic disease become resistant to androgen-deprivation therapy. With 1,500,000 new cases and 397,000 deaths worldwide, prostate cancer is the world’s second most frequent cancer and the fifth leading cause of cancer death among men. It is estimated that there are at least 3,500,000 men living with prostate cancer in the United States and 2,500,000 in Europe. Approximately 2% of all prostate cancer cases are mCRPC, and practically all patients with metastatic disease will become resistant to androgen-deprivation therapy. As such, the population with mCRPC eligible to chemotherapy is around 50,000 in the EU and 70,000 in the USA. Study AB12003 was a prospective, placebo-controlled, double-blind, randomized, phase 3 trial that evaluated masitinib (6.0 mg/kg/d) in combination with docetaxel (IV 75 mg/m² plus prednisone for up to 10 cycles) as a first-line treatment for metastatic castrate-resistant prostate cancer (mCRPC). Eligible patients were chemotherapy-naïve with confirmed mCRCP, had progressed on previous abiraterone treatment or were indicated for docetaxel treatment, and had an ECOG performance status score of =1. Primary analysis was performed on a pre-specified targeted subgroup, defined as patients with baseline alkaline phosphatase (ALP) levels =250 IU/L, and on the overall population. The primary endpoint was progression-free survival (PFS) (PCWG2 definition). The study was successful if the improvement in median PFS relative to the control reached a 3.9% level of significance for the target subgroup (alpha split with fallback procedure to conserve the overall type-I error at 5% for the overall study cohort). The primary analysis was based on 450 patients in the targeted subgroup (ALP = 250 IU/L). The overall study cohort comprised 712 patients.

French (CAC) Pharma Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

AB Science Patent For Masitinib In The Treatment Of Metastatic Castrate Resistant Prostate Cancer Formally Granted In The United States With Protection Until 2042

MEDCL: Long Acting Schizophrenia Injection Pipeline Will Drive Future Share Price Upside

SAN: Future Upside Will Hinge On AI Execution Across R&D Workflows

EAPI: Revenue Contraction And Margin Pressure Will Continue To Restrain Future Earnings

IPN: Oncology And Rare Liver Pipeline Progress Will Shape Balanced Future Outlook

VIRP: Stable Assumptions And Extraordinary Meeting Will Support Future Upside Repricing

Upcoming dividend of €1.35 per share

Advicenne S.A. Announces Board Changes

Dividend increased to €0.93

THX Pharma Société Anonyme, Annual General Meeting, Jun 23, 2026